HONG KONG, August 7, 2026: Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma; 2335.HK) has reported that its proprietary drug candidate MT200605 achieved the primary endpoint in a Phase II clinical trial for acute ischemic stroke (AIS), with statistically significant results. The company announced the topline data on August 3, 2026.
The multicenter, randomized, double-blind, placebo-controlled trial enrolled 360 subjects with AIS. The proportion of patients achieving a modified Rankin Scale (mRS) score of 0–1 at 90 days was higher in both the medium- and high-dose MT200605 groups compared to placebo, with the high-dose group showing more than double the rate seen in the placebo group. These results were statistically significant, and similar efficacy trends were observed across secondary endpoints.
Favorable safety and tolerability profile
No serious adverse events related to MT200605 were reported during the trial. Treatment-emergent adverse events of grade 3 or higher were evenly distributed among all groups, and no new safety risks were identified, indicating good tolerability. The company said these findings provide a strong rationale for advancing MT200605 to further clinical development.
Unique multi-stage neuroprotection mechanism
Micot Pharma highlighted that MT200605 is, to its knowledge, the only clinical-stage small-molecule agonist that crosses the blood-brain barrier, targets the BDNF/TrkB pathway, and provides neurorestorative activity. The drug acts across three stages of ischemic brain injury: improving blood flow by inducing vasodilation and enhancing cerebral perfusion (upstream), limiting acute injury by scavenging reactive oxygen species and reducing neuronal apoptosis (midstream), and promoting neural repair through sustained TrkB activation (downstream).
Unlike existing drugs that focus on single or dual targets, MT200605 establishes a therapeutic cascade of blood flow improvement, cellular protection, and neural restoration. The company said this could position MT200605 as the first neuroprotectant in China to achieve Class I recommendation and Level A evidence in clinical guidelines.
Presentation at World Stroke Congress 2026
The organizing committee of the 18th World Stroke Congress (WSC 2026) has accepted Micot Pharma’s abstract, “MT200605: A Novel Bifunctional Neuroprotectant for Ischemic Stroke,” for oral presentation. The company will present non-clinical and Phase I results to global stroke experts at the congress, reflecting international academic recognition of the drug’s mechanism of action.
Large unmet need and market potential
According to the Global Burden of Disease study, there were 7.8 million new cases of ischemic stroke worldwide in 2021. In China, over 26 million people have had a stroke, with 4 million new cases annually. The Global Stroke Report 2025 estimates the global economic burden of stroke at $890 billion in 2021, projected to exceed $1.8 trillion by 2050. Currently, no neuroprotective agent for AIS has been approved in Europe or the US, and drugs used in parts of Asia lack high-level evidence-based support.
In China, neuroprotectants such as butylphthalide and edaravone/edaravone dexborneol only have Level II recommendations with Grade B evidence. Data from Moyi Pharma Intelligence shows the peak terminal market size for two mainstream neuroprotectants exceeds 6 billion RMB, while the overall market for traditional Chinese medicines for cardiovascular and cerebrovascular diseases reached 93.5 billion RMB in 2024.
National and international recognition for MT200605
In May 2026, MT200605 was selected for the National Science and Technology Major Project for Innovative Drug Development and incorporated into China’s national strategy for cardiovascular and cerebrovascular diseases. The drug also received Orphan Drug Designation from the US FDA for Huntington’s disease in March 2026. Micot Pharma said these recognitions, along with the WSC 2026 selection, mark a milestone in the drug’s transition from laboratory research to global clinical practice.
Disclaimer: This article is based on a press release provided by the concerned organisation and has been edited for style and clarity with the assistance of AI tools. BusinessFortnight does not verify, endorse, or take responsibility for the claims, figures, or statements made in the original release.
